FDA approves Ironwood’s gout combination drug
Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
Earlier decision to reject drug reversed.
Otezla cheap and convenient, but less effective than rivals, says NICE.
But attendees warned to expect “oceanic” weather.